• English
  • Korean
  • Chinese
表紙
市場調査レポート - 246373

トキソプラズマ症治療薬市場:パイプライン分析と市場予測

Toxoplasmosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019

発行 GlobalData
出版日 ページ情報 英文 56 Pages
価格
トキソプラズマ症治療薬市場:パイプライン分析と市場予測 Toxoplasmosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019
出版日: 2012年07月02日 ページ情報: 英文 56 Pages
概要

トキソプラズマ症治療薬市場は2011年の11億5,000万米ドルからCAGR3.9%で成長し、2019年には15億5,000万米ドルの規模になる見通しです。地球温暖化やその他の人為的原因により、トキソプラズマ症の罹患率は今後も上昇するものと推測されます。

当レポートでは、世界のトキソプラズマ症治療薬市場についてパイプライン分析および市場予測を行っており、市場の特徴をはじめ、競合、パイプラインなどを評価分析し、将来の市場競争、企業プロファイルを盛り込んで、概略以下の構成でお届けします。

1 目次

  • 1.1 表一覧
  • 1.2 図一覧

2 トキソプラズマ症治療薬 - イントロダクション

  • 2.1 疾患概要
    • 2.1.1 トキソプラズマ・ゴンディのタイプ
    • 2.1.2 ライフサイクルおよび媒介
  • 2.2 疫学
    • 2.2.1 これまでのトキソプラズマ症
    • 2.2.2 これからのトキソプラズマ症
  • 2.3 病因
    • 2.3.1 食物媒介/li>
    • 2.3.2 先天感染
    • 2.3.3 動物感染
    • 2.3.4 まれな感染経路
  • 2.4 病態生理学
  • 2.5 兆候および症状
  • 2.6 一般的な 診断検査
    • 2.6.1 診断用検査の種類
  • 2.7 トキソプラズマ症の治療および管理オプション
    • 2.7.1 妊娠中に感染したトキソプラズマ症の管理
    • 2.7.2 先天性トキソプラズマ症
    • 2.7.3 眼トキソプラズマ症
    • 2.7.4 トキソプラズマ症 − 免疫正常患者
  • 2.8 GlobalData パイプラインレポートガイダンス

3 トキソプラズマ症治療薬 - 市場特性

  • 3.1 トキソプラズマ症 治療薬市場規模 - 世界
  • 3.2 トキソプラズマ症 治療薬市場予測 - 世界
  • 3.3 トキソプラズマ症 治療薬市場規模 - 米国
  • 3.4 トキソプラズマ症 治療薬市場予測 - 米国
  • 3.5 トキソプラズマ症 治療薬市場規模 - フランス
  • 3.6 トキソプラズマ症 治療薬市場予測 - フランス
  • 3.7 トキソプラズマ症 治療薬市場規模 - ドイツ
  • 3.8 トキソプラズマ症 治療薬市場予測 - ドイツ
  • 3.9 トキソプラズマ症 治療薬市場規模 - イタリア
  • 3.10 トキソプラズマ症 治療薬市場予測 - イタリア
  • 3.11 トキソプラズマ症 治療薬市場規模 - スペイン
  • 3.12 トキソプラズマ症 治療薬市場予測 - スペイン
  • 3.13 トキソプラズマ症 治療薬市場規模 - 英国
  • 3.14 トキソプラズマ症 治療薬市場予測 - 英国
  • 3.15 トキソプラズマ症 治療薬市場規模 - 日本
  • 3.16 トキソプラズマ症 治療薬市場予測 - 日本
  • 3.17 トキソプラズマ症治療薬市場の成長促進要因および障壁
    • 3.17.1 成長促進要因
    • 3.17.2 障壁
  • 3.18 市場機会およびアンメット・ニーズ分析
  • 3.19 要点

4 トキソプラズマ症治療薬 - 競合評価

  • 4.1 概要
  • 4.2 戦略的競合評価
  • 4.3 上市製品のプロファイル
    • 4.3.1 Daraprim (pyrimethamine)
    • 4.3.2 Spiramycin
    • 4.3.3 Sulfadiazine
    • 4.3.4 Folinic Acid
  • 4.4 要点

5 トキソプラズマ症治療薬 - パイプライン評価

  • 5.1 概要
  • 5.2 戦略的パイプライン評価
    • 5.2.1 第3相臨床パイプライン
  • 5.3 要点

6 トキソプラズマ症治療薬 - 臨床試験マッピング

  • 6.1 地域/国別
  • 6.2 相別
  • 6.3 治験ステータス別
  • 6.4 スポンサー別
  • 6.5 有力なスポンサー
  • 6.6 治験参加企業

7 トキソプラズマ症治療薬 - 戦略的評価

  • 7.1 将来の市場に影響を与える主な事象
  • 7.2 将来の市場競争への影響

8 ライセンス契約および提携取引

9 KOL の識見

10 付録

  • 10.1 市場定義
  • 10.2 頭字語
  • 10.3 参考文献
  • 10.4 調査方法
    • 10.4.1 調査範囲
    • 10.4.2 二次調査
    • 10.4.3 予測
    • 10.4.4 一次調査
    • 10.4.5 専門委員会によるバリデーション
  • 10.5 お問い合わせ
  • 10.6 免責事項

表一覧

図一覧


目次

Abstract

Toxoplasmosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Summary

GlobalData, the industry analysis specialist, has released its new report, "Toxoplasmosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019". The report is an essential source of information and analysis on the global Toxoplasmosis Therapeutics market. The report identifies the key trends shaping and driving the global Toxoplasmosis Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Toxoplasmosis Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Toxoplasmosis Therapeutics market. Its scope includes -

  • Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Toxoplasmosis Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
  • Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
  • Analysis of the current and future competition in the seven key countries Toxoplasmosis Therapeutics market.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Toxoplasmosis Therapeutics market.
  • Analysis of key recent licensing and partnership agreements in Toxoplasmosis Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global Toxoplasmosis Therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Toxoplasmosis Therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • What's the next big thing in the global Toxoplasmosis Therapeutics market landscape? - Identify, understand and capitalize.

TOC

1 Table of Contents

1 Table of Contents 3

  • 1.1 List of Tables 5
  • 1.2 List of Figures 5

2 Toxoplasmosis Therapeutics - Introduction 6

  • 2.1 Disease Overview 6
    • 2.1.1 Types of Toxoplasma gondii Strain 7
    • 2.1.2 Life Cycle and Transmission 7
  • 2.2 Epidemiology 7
    • 2.2.1 Historic Epidemiology (2006-2011) 8
    • 2.2.2 Forecast Epidemiology (2011-2019) 9
  • 2.3 Etiology 10
    • 2.3.1 Food-borne Transmission 10
    • 2.3.2 Congenital Transmission 10
    • 2.3.3 Zoonotic Transmission 10
    • 2.3.4 Rare Instances of Transmission 10
  • 2.4 Pathophysiology 10
  • 2.5 Signs and Symptoms 11
  • 2.6 Commonly Used Diagnostic Tests 12
    • 2.6.1 Types of Diagnostic Test 12
  • 2.7 Treatment and Management Options for Toxoplasmosis 13
    • 2.7.1 Management of Toxoplasmosis Infection during Gestation 14
    • 2.7.2 Congenital Toxoplasmosis 14
    • 2.7.3 Ocular Toxoplasmosis 15
    • 2.7.4 Toxoplasmosis in Immunocompetent Patients 15
  • 2.8 GlobalData Pipeline Report Guidance 16

3 Toxoplasmosis Therapeutics - Market Characterization 17

  • 3.1 Toxoplasmosis Therapeutics Market Size (2006-2011) - Global 17
  • 3.2 Toxoplasmosis Therapeutics Market Forecast (2011-2019) - Global 19
  • 3.3 Toxoplasmosis Therapeutics Market Size (2006-2011) - The US 20
  • 3.4 Toxoplasmosis Therapeutics Market Forecast (2011-2019) - The US 21
  • 3.5 Toxoplasmosis Therapeutics Market Size (2006-2011) - France 22
  • 3.6 Toxoplasmosis Therapeutics Market Forecast (2011-2019) - France 23
  • 3.7 Toxoplasmosis Therapeutics Market Size (2006-2011) - Germany 24
  • 3.8 Toxoplasmosis Therapeutics Market Forecast (2011-2019) - Germany 25
  • 3.9 Toxoplasmosis Therapeutics Market Size (2006-2011) - Italy 26
  • 3.10 Toxoplasmosis Therapeutics Market Forecast (2011-2019) - Italy 27
  • 3.11 Toxoplasmosis Therapeutics Market Size (2006-2011) - Spain 28
  • 3.12 Toxoplasmosis Therapeutics Market Forecast (2011-2019) - Spain 29
  • 3.13 Toxoplasmosis Therapeutics Market Size (2006-2011) - The UK 30
  • 3.14 Toxoplasmosis Therapeutics Market Forecast (2011-2019) - The UK 31
  • 3.15 Toxoplasmosis Therapeutics Market Size (2006-2011) - Japan 32
  • 3.16 Toxoplasmosis Therapeutics Market Forecast (2011-2019) - Japan 33
  • 3.17 Drivers and Barriers for the Toxoplasmosis Therapeutics Market 34
    • 3.17.1 Drivers for the Toxoplasmosis Therapeutics Market 34
    • 3.17.2 Barriers for the Toxoplasmosis Therapeutics Market 34
  • 3.18 Opportunity and Unmet Need Analysis 35
  • 3.19 Key Takeaway 36

4 Toxoplasmosis Therapeutics - Competitive Assessment 37

  • 4.1 Overview 37
  • 4.2 Strategic Competitor Assessment 37
  • 4.3 Product Profiles of the Marketed Products in the Toxoplasmosis Therapeutics Market 38
    • 4.3.1 Daraprim (pyrimethamine) 38
    • 4.3.2 Spiramycin 39
    • 4.3.3 Sulfadiazine 39
    • 4.3.4 Folinic Acid 40
  • 4.4 Key Takeaway 40

5 Toxoplasmosis Therapeutics - Pipeline Assessment 41

  • 5.1 Overview 41
  • 5.2 Strategic Pipeline Assessment 41
    • 5.2.1 Toxoplasmosis Therapeutics - Phase III Clinical Pipeline 41
  • 5.3 Key Takeaway 41

6 Toxoplasmosis Therapeutics - Clinical Trial Mapping 42

  • 6.1 Clinical Trials by Region and Country 42
  • 6.2 Clinical Trials by Phase 43
  • 6.3 Clinical Trials by Trial Status 44
  • 6.4 Clinical Trial Mapping by Sponsors 45
  • 6.5 Prominent Sponsors 46
  • 6.6 Companies Participating in Toxoplasmosis Therapeutics Clinical Trials 46

7 Toxoplasmosis Therapeutics - Strategic Assessment 47

  • 7.1 Key Events Impacting the Future Market 47
  • 7.2 Toxoplasmosis Therapeutics: Implications for Future Market Competition 47

8 Toxoplasmosis Therapeutics Market - Licensing and Partnership Deals 48

9 Toxoplasmosis Therapeutics Market - KOL Insights, 2012 49

10 Toxoplasmosis Therapeutics - Appendix 50

  • 10.1 Market Definitions 50
  • 10.2 Acronyms 50
  • 10.3 Bibliography 50
  • 10.4 Research Methodology 52
    • 10.4.1 Coverage 52
    • 10.4.2 Secondary Research 52
    • 10.4.3 Forecasting 53
    • 10.4.4 Primary Research 55
    • 10.4.5 Expert Panel Validation 56
  • 10.5 Contact Us 56
  • 10.6 Disclaimer 56

List of Tables

1.1 List of Tables

  • Table 1: Toxoplasmosis Therapeutics Market, Global, Prevalence, 2006-2011 8
  • Table 2: Toxoplasmosis Therapeutics Market, Global, Prevalence, 2011-2019 9
  • Table 3: Alternative Antibiotics Used in Ocular Toxoplasmosis 15
  • Table 4: Toxoplasmosis Therapeutics Market, Global, Revenue ($m), 2006-2011 18
  • Table 5: Toxoplasmosis Therapeutics Market, Global, Forecast ($m), 2011-2019 19
  • Table 6: Toxoplasmosis Therapeutics Market, The US, Revenue ($m), 2006-2011 20
  • Table 7: Toxoplasmosis Therapeutics Market, The US, Forecast ($m), 2011-2019 21
  • Table 8: Toxoplasmosis Therapeutics Market, France, Revenue ($m), 2006-2011 22
  • Table 9: Toxoplasmosis Therapeutics Market, France, Forecast ($m), 2011-2019 23
  • Table 10: Toxoplasmosis Therapeutics Market, Germany, Revenue ($m), 2006-2011 24
  • Table 11: Toxoplasmosis Therapeutics Market, Germany, Forecast ($m), 2011-2019 25
  • Table 12: Toxoplasmosis Therapeutics Market, Italy, Revenue ($m), 2006-2011 26
  • Table 13: Toxoplasmosis Therapeutics Market, Italy, Forecast ($m), 2011-2019 27
  • Table 14: Toxoplasmosis Therapeutics Market, Spain, Revenue ($m), 2006-2011 28
  • Table 15: Toxoplasmosis Therapeutics Market, Spain, Forecast ($m), 2011-2019 29
  • Table 16: Toxoplasmosis Therapeutics Market, The UK, Revenue ($m), 2006-2011 30
  • Table 17: Toxoplasmosis Therapeutics Market, The UK, Forecast ($m), 2011-2019 31
  • Table 18: Toxoplasmosis Therapeutics Market, Japan, Revenue ($m), 2006-2011 32
  • Table 19: Toxoplasmosis Therapeutics Market, Japan, Forecast ($m), 2011-2019 33
  • Table 20: Toxoplasmosis Therapeutics-Phase III Pipeline, 2012 41
  • Table 21: Toxoplasmosis Therapeutics - Clinical Trials by Country, 2012 42
  • Table 22: Toxoplasmosis Therapeutics - Clinical Trials by Phase, 2012 43
  • Table 23: Toxoplasmosis Therapeutics - Clinical Trials by Status, 2012 44
  • Table 24: Toxoplasmosis Therapeutics - Overall Sponsors, 2012 45
  • Table 25: Toxoplasmosis Therapeutics - Prominent Sponsors, 2012 46
  • Table 26: Toxoplasmosis Therapeutics - Company Participating in Therapeutics Clinical Trials, 2012 46
  • Table 27: Toxoplasmosis-Global, Deals, 2012 48
  • Table 28: Toxoplasmosis Therapeutics Market, Global, KOL Insights, 2012 49

List of Figures

1.2 List of Figures

  • Figure 1: Diagnosis Algorithm for Congenital Toxoplasmosis 12
  • Figure 2: Approaches for the Treatment of Pregnant Women 14
  • Figure 3: Toxoplasmosis Therapeutics Market, Global, Revenue ($m), 2006-2011 18
  • Figure 4: Toxoplasmosis Therapeutics Market, Global, Forecast ($m), 2011-2019 19
  • Figure 5: Toxoplasmosis Therapeutics Market, The US, Forecast ($m), 2006-2011 20
  • Figure 6: Toxoplasmosis Therapeutics Market, The US, Forecast ($m), 2011-2019 21
  • Figure 7: Toxoplasmosis Therapeutics Market, France, Revenue ($m), 2006-2011 22
  • Figure 8: Toxoplasmosis Therapeutics Market, France, Forecast ($m), 2011-2019 23
  • Figure 9: Toxoplasmosis Therapeutics Market, Germany, Revenue ($m), 2006-2011 24
  • Figure 10: Toxoplasmosis Therapeutics Market, Germany, Forecast ($m), 2011-2019 25
  • Figure 11: Toxoplasmosis Therapeutics Market, Italy, Revenue ($m), 2006-2011 26
  • Figure 12: Toxoplasmosis Therapeutics Market, Italy, Forecast ($m), 2011-2019 27
  • Figure 13: Toxoplasmosis Therapeutics Market, Spain, Revenue ($m), 2006-2011 28
  • Figure 14: Toxoplasmosis Therapeutics Market, Spain, Forecast ($m), 2011-2019 29
  • Figure 15: Toxoplasmosis Therapeutics Market, The UK, Revenue ($m), 2006-2011 30
  • Figure 16: Toxoplasmosis Therapeutics Market, The UK, Forecast ($m), 2011-2019 31
  • Figure 17: Toxoplasmosis Therapeutics Market, Japan, Revenue ($m), 2006-2011 32
  • Figure 18: Toxoplasmosis Therapeutics Market, Japan, Forecast ($m), 2011-2019 33
  • Figure 19: Opportunity and Unmet Need in the Toxoplasmosis Therapeutics Market 36
  • Figure 20: Toxoplasmosis Therapeutics - Strategic Competitor Assessment, 2012 38
  • Figure 21: Toxoplasmosis Therapeutics - Clinical Trials by Country, 2012 42
  • Figure 22: Toxoplasmosis Therapeutics - Clinical Trials by Phase, 2012 43
  • Figure 23: Toxoplasmosis Therapeutics - Clinical Trials by Status, 2012 44
  • Figure 24: Toxoplasmosis Therapeutics - Overall Sponsors, 2012 45
  • Figure 25: Toxoplasmosis Therapeutics Market, Drivers and Barriers, 2012 47
  • Figure 26: Implications for Future Market Competition in the Toxoplasmosis Therapeutics Market, 2012 47
  • Figure 27: GlobalData Market Size Estimation 53
  • Figure 28: GlobalData Market Forecasting Model 55
Back to Top